RhBio

RhBio is a clinical-stage biotechnology company that operates as a strategic development vehicle, primarily known as a joint venture between Rhizen Pharmaceuticals and Curon Biopharmaceutical. The company is dedicated to the advancement and commercialization of innovative oncology therapeutics, with a primary focus on the Greater China market. Its lead candidate, Tenalisib (RP6530), is a highly selective, orally active dual inhibitor of the PI3K delta and gamma isoforms. Tenalisib is currently being evaluated in Phase 2 clinical trials for the treatment of various hematological malignancies, including peripheral and cutaneous T-cell lymphomas. RhBio leverages the integrated drug discovery and clinical development expertise of its parent organizations to address significant unmet medical needs in the oncology space. The company aims to provide novel, targeted small molecule options for patients with refractory or relapsed cancers.